PPARA and metabolic dysfunction-associated steatotic liver disease: PPAR agonists have been well supported as potential drugs for NAFLD (Laurin et al., 1996; Hertz and Bar-Tana, 1998; Neuschwander-Tetri et al., 2003; Kawaguchi et al., 2004; Fernández-Miranda et al., 2008; Ratziu et al., 2008, 2010; Nan et al., 2009; Torres et al., 2011; Zhang et al., 2015; Abd El-Haleim et al., 2016; Liss and Finck, 2017), whereas statins showed positive association yet less literature documentation (Pastori et al., 2015; Park et al., 2016; Sigler et al., 2018; Bravo et al., 2019).